Dr. Lewis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12605 E 16th Ave
Aurora, CO 80045Phone+1 720-848-0000
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2002 - 2004
University of California (Irvine)Residency, Internal Medicine, 1999 - 2002
Albany Medical CollegeClass of 1999
Certifications & Licensure
CA State Medical License 2001 - Present
CO State Medical License 2003 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
- Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients Start of enrollment: 2013 Apr 01
- Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) Start of enrollment: 2019 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 2050 citationsCombined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsKeith T. Flaherty, J. R. Infante, Adil Daud, Rene Gonzalez, Richard F. Kefford
The New England Journal of Medicine. 2012-10-31 - 228 citationsOverall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V. Long, Jeffrey S. Weber, Jeffrey R. Infante, Kevin B. Kim, Adil Daud
Journal of Clinical Oncology. 2016-09-19 - 1659 citationsSurvival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibJeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, Rene Gonzalez, Anna C. Pavlick
The New England Journal of Medicine. 2012-02-23
Press Mentions
Next-Generation Immunotherapy Drug Shows Continued Promise in Several Advanced-Stage CancersMay 26th, 2022- FDA Approves Libtayo for Advanced Basal Cell CarcinomaFebruary 10th, 2021
- FDA Approves Libtayo for Locally Advanced and Metastatic Basal Cell CarcinomaFebruary 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
